Alteogen Inc 196170
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- KRW 178,000.00
- Day Range
- KRW 172,700.00–189,000.00
- 52-Week Range
- —–—
- Bid/Ask
- KRW 186,800.00 / KRW 186,900.00
- Market Cap
- KRW 9.91 Tril
- Volume/Avg
- 2.4 Mil / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 96.37
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alteogen Inc Inc is engaged in the development and manufacture of next-generation biopharmaceuticals using NexP Fusion Technology. It also develops & markets biobetters and biosimilars by partnerships with pharmaceutical companies. It focuses on the areas such as biobetters, a proprietary antibody-drug conjugate, and antibody biosimilars with complexity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 125
- Website
- http://www.alteogen.com
Comparables
Valuation
|
Metric
|
196170
|
323990
|
310210
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 64.61 | 4.45 | 8.20 |
Price/Sales | 96.37 | — | 756.26 |
Price/Cash Flow | 3,204.91 | — | — |
Price/Earnings
196170
323990
310210
Financial Strength
|
Metric
|
196170
|
323990
|
310210
|
|---|---|---|---|
Quick Ratio | 1.41 | 54.78 | 4.85 |
Current Ratio | 1.43 | 55.43 | 4.91 |
Interest Coverage | −12.05 | −260.75 | −18.54 |
Quick Ratio
196170
323990
310210
Profitability
|
Metric
|
196170
|
323990
|
310210
|
|---|---|---|---|
Return on Assets (Normalized) | −0.59% | −29.47% | −42.78% |
Return on Equity (Normalized) | −1.02% | −30.90% | −96.10% |
Return on Invested Capital (Normalized) | −3.22% | −33.70% | −44.97% |
Return on Assets
196170
323990
310210
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jjxllkgpyx | Gddt | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lmgmrbf | Msgchx | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fbvvkzpdx | Qkxdqrt | $106.7 Bil | |
MRNA
| Moderna Inc | Pmftwnvqn | Trrs | $50.8 Bil | |
BNTX
| BioNTech SE ADR | Gqkvlvwyb | Xvdc | $22.4 Bil | |
ARGX
| argenx SE ADR | Ttsqvsfx | Hdvr | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ykbznbzk | Ntgrxl | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bqkzkjq | Thwfgph | $14.6 Bil | |
INCY
| Incyte Corp | Lmgcjsnt | Zhxmng | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vfqlfsvfr | Cfsfdy | $12.6 Bil |